• BVI heads to ESCRS 2026 with a comprehensive program centered on innovation, education and surgeon collaboration.
• European launch of Virtuoso and global availability of the complete ISOPURE SERENITY portfolio highlight a congress agenda featuring wet labs, educational sessions and peer-to-peer clinical engagement.

WALTHAM, Mass., August 19^th, 2026 — As the global ophthalmic community turns its attention to London for the 2026 European Society of Cataract and Refractive Surgeons (ESCRS) Congress, BVI, a leading global ophthalmic device company, is preparing to showcase how advanced technology, expanded cataract solutions, surgeon education and clinical collaboration come together to help shape the future of ophthalmic surgery. Read More

• New facility expands opportunities for hands-on learning, professional development, and clinical collaboration.
• BVI plans to expand the Hub's educational offerings through structured programs covering cataract surgery, glaucoma and vitreoretinal procedures, premium intraocular lenses, and practice development.

SANT CUGAT, Spain, June 15^th, 2026 — As ophthalmology becomes increasingly specialized and technology-driven, demand for practical surgical education continues to grow. To support that need, BVI today announced the opening of the BVI Experience Hub, a dedicated facility designed to support ophthalmic training, professional development, and clinical collaboration for surgeons and clinical teams from Europe and around the world. Read More

• The council will serve as an advisory group, guiding BVI on market insights, clinical practice and surgical education across Europe.
• The initiative builds on the momentum of BVI’s US Surgical Leadership Council, extending its collaborative model to key European markets. Read More

• CE Mark under the European Union Medical Device Regulation (EU MDR) achieved for Virtuoso®, BVI’s first dual-function phaco-vitrectomy platform designed to deliver advanced control, efficiency, and versatility for both cataract and vitreoretinal surgery.
• First patient successfully treated at LMU Klinikum in Munich, Germany, in December 2025. This milestone builds on Virtuoso®’s presence across key 2025 industry forums, including EURETINA, ESCRS, and FloRETINA, and continued into 2026 at the Munich Retina Meeting, where the platform was featured in its first live surgery, reinforcing its design focus on fluidics stability, workflow efficiency, and the real-world demands of ophthalmic surgery.

WALTHAM, Mass., April 20th, 2026 — BVI, a global leader in ophthalmic device innovation, today announced that Virtuoso® has received the CE Mark under the European Union Medical Device Regulation (EU MDR), enabling commercialization across markets recognizing the CE Mark. Virtuoso® is BVI’s next-generation phaco-vitrectomy surgical platform, a dual-function system designed to support both cataract and vitreoretinal procedures on a single, integrated platform. Read More

Waltham, MA., January 19th, 2026 – BVI, a global leader in the ophthalmic device market, announced today the appointment of Jim Hollingshead as President & Chief Executive Officer. Hollingshead succeeds Shervin Korangy, who will continue to serve as an advisor to BVI and begin a new role as senior advisor to TPG Capital.  Read More